Skip to main content
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet 

Investors & Media

Corporate Profile

Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium dificile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its microbiom... More

Recent NewsMore
Seres Therapeutics Reports Second Quarter Financial Results and Provides Operational Progress Update
- Comprehensive review of initial SER-109 Phase 2 study data underway - - Strong cash position to support operations well into 2018, and through the anticipated Phase 1b study read-outs for SER-287 and SER-262 – - Conference call at 8:30 AM ET today - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 11, 2016-- Seres Therapeutics Inc., (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today reported second quarter... 
Seres Therapeutics to Host Second Quarter 2016 Financial Results and Operational Progress Conference Call and Webcast on August 11, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 5, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that management will host a conference call and live audio webcast on Thursday, August 11, 2016 at 8:30 a.m. ET to discuss second quarter 2016 results. This Smart News Release features multimedia. View the full release here: To access t... 
Seres Therapeutics Announces Interim Results from SER-109 Phase 2 ECOSPOR Study in Multiply Recurrent Clostridium difficile Infection
- Primary efficacy endpoint was not achieved - - Conference call at 8:30 AM ET today - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 29, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, today announced interim 8-week results from the ongoing SER-109 Phase 2 ECOSPORTM clinical study for the prevention of multiply recurrent Clostridium difficile infection (CDI). The study’s primary endpoint of r... 
There are currently no upcoming events scheduled.
Stock Quote
 - 0.29 (0.00%)
10/27/16 4:00 p.m. ET
Refresh quote
E-mail Alerts
Sign up to receive e-mail alerts whenever Seres Therapeutics, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Request Information

Obtain investor relations information by contacting us.

Data provided by Nasdaq. Minimum 15 minutes delayed.